# A Pilot Study of Recombinant Human Relaxin (rhRlx) in Compensated Congestive Heart Failure

> **NCT00259116** · PHASE2 · COMPLETED · sponsor: **Corthera, Inc.(formerly BAS Medical, Inc.), a member of the Novartis group of companies** · enrollment: 18 (—)

## Conditions studied

- Heart Failure, Congestive

## Interventions

- **DRUG:** Relaxin

## Key facts

- **NCT ID:** NCT00259116
- **Lead sponsor:** Corthera, Inc.(formerly BAS Medical, Inc.), a member of the Novartis group of companies
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-11
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 18 (—)
- **Last updated:** 2009-04-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00259116

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00259116, "A Pilot Study of Recombinant Human Relaxin (rhRlx) in Compensated Congestive Heart Failure". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00259116. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*